Search
Cefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationalCefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. … [FDA Label] Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels.
Lacosamide
go.drugbank.com/drugs/DB06218ApprovedInvestigational[A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008.
Products: LACOSAMIDE EG, Nra-lacosamideDiamorphine
go.drugbank.com/drugs/DB01452ApprovedIllicit(Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs.
Amodiaquine
go.drugbank.com/drugs/DB00613ApprovedInvestigationalA 4-aminoquinoquinoline compound with anti-inflammatory properties.
Nilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered si...
Castor oil
go.drugbank.com/drugs/DB11113ApprovedNutraceuticalVet approvedCastor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products. … It is an FDA-approved food additive directly added to food products for human consumption.
Iodine povacrylex
go.drugbank.com/drugs/DB09537ApprovedDuraPrep solution is indicated for use as a patient preoperative skin preparation, for the preparation of the skin prior to surgery and to help reduce bacteria that can potentially cause skin infection
Relatlimab
go.drugbank.com/drugs/DB14851ApprovedInvestigational[L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … [A246155] Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor [nivolumab] in the combination product Opdualag (Bristol-Myers Squibb), for the treatment of unresectable or metastatic
Oxethazaine
go.drugbank.com/drugs/DB12532ApprovedWithdrawn[A33104] Oxetacaine is approved by Health Canada since 1995 for its use as an antacid combination in over-the-counter preparations.
Succinic acid
go.drugbank.com/drugs/DB00139ApprovedInvestigationalNutraceutical(Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851)